Small Business: Therapeutic Development for Alzheimer’s Disease and Related Dementias (ADRD) and Neurodegenerative Disorders – AN (11)
This review panel reviews applications dealing with basic and clinical aspects of drug discovery in treatment of aging and neurodegenerative disorders, including mild-cognitive impairment, Alzheimer’s disease and related dementias, movement degenerative disorders such as Parkinson’s, Huntington’s, amyotrophic lateral sclerosis. Approaches are those of medicinal chemistry and pre-clinical development, toxicology, and some clinical studies to establish proof-of-principle for new or repurposing existing drugs. The arrange of therapeutic formats include small molecule drugs and biologics such as molecular manipulation and engineering, gene and stem cell therapies, and proteins/neuropeptides that interact with and modulate neuroreceptors, transporters and transducers.
Review Dates
Topics
- Interventions for senescence of nerve cells, cognitive aging, and mild cognitive impairment (MCI)
- Alzheimer’s disease (AD)
- Alzheimer’s related dementia (ADRD) including frontotemporal dementia (FTD), Lewy body dementia (LBD), Limbic-predominant age-related TDP-43 encephalopathy (LATE), and Creutzfeldt-Jakob disease (CJD)
- Neurodegenerative movement disorders such as Parkinson’s diseases (PD), essential tremor, ataxia, Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), etc.
